Plain-English, clinically-cited guides to each major psychedelic therapy. What it does, what the evidence actually supports, where the law stands, and how access works in 2026.
Peer-reviewed-cited explainers, medically reviewed by Dr. Michael Teplitsky.
Dissociative anesthetic, FDA-approved (as Spravato) for treatment-resistant depression.
US status: Schedule III. Spravato (esketamine) FDA-approved for TRD; ketamine off-label via clinics and telehealth.
Classic tryptamine psychedelic; FDA Breakthrough Therapy designation for depression.
US status: Schedule I federally. Legal regulated access in Oregon (Measure 109) and Colorado (Prop 122). Active FDA Phase 3 trials.
Empathogen for PTSD; FDA rejected Lykos's application August 2024, additional Phase 3 required.
US status: Schedule I. FDA rejected first NDA in August 2024; no approved use. Access primarily via clinical trials.
Country-by-country guide to MDMA legality: Australia's prescribing program, decriminalization in Portugal and the Czech Republic, and the US executive order.
US status: Schedule I federally. No state has legalized MDMA. April 2026 executive order directs FDA/DEA to fast-track psychedelic reviews but does not change MDMA's current legal status.
Amazonian N,N-DMT-containing brew; two US religious exemptions, most access abroad.
US status: Schedule I. Legal only via DEA-recognized religious exemption (UDV, Santo Daime, and two newer churches). Retreats otherwise operate abroad.
The 'bufo' / Colorado River toad psychedelic (5-MeO-DMT, aka toad venom) — a short-acting tryptamine; GH Research's GH001 Phase 2b (2025) showed -15.5 MADRS vs placebo in TRD.
US status: Schedule I. Access via international retreats and a small number of FDA-IND clinical trials (GH Research GH001, others).
The two companies racing to turn synthetic 5-MeO-DMT into an approved depression drug — BPL-003 vs GH001 — compared on trial data, delivery, timeline, and market position.
US status: 5-MeO-DMT is Schedule I; neither BPL-003 nor GH001 is FDA-approved. Both hold FDA clearance to run trials (BPL-003 has Breakthrough Therapy Designation for TRD) and are heading toward Phase 3.
Eli Lilly's completed $2.8B (up to $3.8B) acquisition of AtaiBeckley — what happens to BPL-003 and VLS-01, and what it does and doesn't mean for patients and investors.
US status: BPL-003 and VLS-01 are investigational; neither is FDA-approved. 5-MeO-DMT and N,N-DMT remain Schedule I federally regardless of who owns the drug programs.
Reported expectations for COMP360 pricing: about $50,000 to $65,000 a year, a derived per-dose figure, who might pay, and why no list price exists yet.
US status: COMP360 is investigational and not FDA-approved. Psilocybin is Schedule I federally; outside an authorized clinical trial there is no lawful clinical access.
The 'God molecule' vs regular DMT — two different tryptamines compared on mechanism (5-HT1A vs 5-HT2A), duration, the type of experience, legal status, and clinical research.
US status: Both 5-MeO-DMT and N,N-DMT are Schedule I federally. N,N-DMT possession is decriminalized in Colorado; neither is FDA-approved, though both have active clinical programs for depression.
A 15-minute synthetic 'white-out' vs a 6-hour Amazonian visionary brew — compared on the molecule, duration, setting, safety, legality, and what each is used for.
US status: Both are Schedule I federally. Ayahuasca has two DEA-recognized religious exemptions; 5-MeO-DMT has none. Access to both is mainly through international retreats or clinical trials.
A 15-minute dose-and-discharge non-dual experience vs a 6-hour psilocybin journey — compared on mechanism, protocol, depression evidence, and access.
US status: Both are Schedule I federally. Psilocybin has regulated legal access in Oregon and Colorado; 5-MeO-DMT does not. Both have active clinical programs for treatment-resistant depression.
The only psychedelic with strong opioid-addiction evidence — and serious cardiac risk. Covers the Texas $50M IMPACT trial and legal retreat options.
US status: Schedule I. No FDA-approved use. Legal access is limited to FDA-IND trials (Texas IMPACT, DemeRx) and international clinics.
State-by-state and country-by-country guide to ibogaine legality: Texas/Arizona research funding, Costa Rica and Mexico's unscheduled status, and where medical prescribing is permitted.
US status: Schedule I federally. No FDA-approved use. Texas (SB 2308, $50M) and Arizona (HB 2871, $5M) fund clinical research, not access; Kentucky's 2024 funding effort did not pass.
Classic long-acting psychedelic; Definium Therapeutics' DT120 (formerly MindMed's MM120) reported positive Phase 3 GAD results in both Voyage (Aug 2026) and Panorama (Sep 2026).
US status: Schedule I. No FDA-approved use. DT120 (formerly MindMed's MM120) Phase 3 Voyage (Aug 2026) and confirmatory Panorama (Sep 2026) both reported positive topline results.
N,N-dimethyltryptamine — Schedule I federally; decriminalized in Colorado; the active compound in ayahuasca.
US status: Schedule I. Personal-use possession decriminalized in Colorado (Prop 122). Four religious organizations hold DEA exemptions for ayahuasca use (UDV, Santo Daime, Iowaska, Church of Gaia).
State-by-state and country-by-country guide to DMT legality: Colorado decrim, DEA religious exemptions, and 4-AcO-DMT analogue law.
US status: Schedule I federally. Personal-use possession decriminalized in Colorado (Prop 122). Four religious organizations hold DEA exemptions for ayahuasca use (UDV, Santo Daime, Iowaska, Church of Gaia).
What the April 18, 2026 executive order on psychedelics does — Priority Vouchers, $50M ARPA-H funding, Right to Try, and what it does not do.
US status: Executive order signed April 18, 2026. Directs FDA Priority Vouchers, Right to Try pathway for investigational psychedelics, $50M ARPA-H state-research match, and DEA rescheduling reviews after Phase 3. Does NOT reschedule any psychedelic. All remain Schedule I federally.
Complete list of US cities and counties that decriminalized psilocybin and entheogenic plants — Denver, Oakland, DC, Detroit, Seattle, and 20+ more.
US status: Schedule I federally. City-level deprioritization resolutions do not change state or federal law. They direct local police to treat possession as lowest enforcement priority.
Magic mushroom spores are legal in 46 US states because they contain no psilocybin — illegal in California, Florida, Georgia, and Idaho. Full state-by-state guide.
US status: Spores contain no psilocybin or psilocin and are not federally scheduled. Illegal under state law in California, Florida, Georgia, and Idaho. Germination becomes a federal felony in all 50 states.
4-AcO-DMT (psilacetin) is a psilocybin prodrug not explicitly scheduled — but the Federal Analogue Act treats it as Schedule I when intended for human use.
US status: Not explicitly scheduled federally. Treated as Schedule I under the Federal Analogue Act (21 U.S.C. § 813) when intended for human consumption. Explicitly scheduled in several states including Florida, Georgia, and Louisiana.
4-PrO-DMT is not named in the DEA's August 2026 lists, but the Federal Analogue Act can still reach an unlisted psilocin analogue intended for human use.
US status: Not named in the DEA's August 2026 lists of controlled substances. The DEA states that an unlisted substance can still be treated as a scheduled substance, and the Federal Analogue Act (21 U.S.C. § 813) can apply when it is intended for human consumption. This is not a finding that it is legal.
The FDA's September 14, 2026 hearing gathered input on the future therapeutic use of psychedelic drugs. It approved nothing and changed no schedule.
US status: The hearing did not approve any psychedelic drug, change any Controlled Substances Act schedule, or legalize or decriminalize any substance. Psilocybin, LSD and MDMA remain Schedule I federally; state programs operate under state law.
4-HO-MiPT (miprocin) is not named in the DEA's August 2026 lists, but the Federal Analogue Act can still reach an unlisted psilocin analogue intended for human use.
US status: Not named in the DEA's August 2026 lists of controlled substances. The DEA states that an unlisted substance can still be treated as a scheduled substance, and the Federal Analogue Act (21 U.S.C. § 813) can apply when it is intended for human consumption. This is not a finding that it is legal.
5-MAPB is not named in the DEA's August 2026 lists, but the Federal Analogue Act can still reach an unlisted MDMA analogue intended for human use.
US status: Not named in the DEA's August 2026 lists of controlled substances. The DEA states that an unlisted substance can still be treated as a scheduled substance, and the Federal Analogue Act (21 U.S.C. § 813) can apply when it is intended for human consumption. This is not a finding that it is legal.
MDMA-assisted therapy for PTSD: what the two phase 3 trials reported, why the FDA declined approval in August 2024, and where it is lawfully prescribed.
US status: MDMA is Schedule I federally. The FDA declined to approve MDMA-assisted therapy in August 2024. In Australia, approved psychiatrists can prescribe it for PTSD (since July 2023).
What four peer-reviewed psilocybin trials in depression reported, and where COMPASS Pathways' phase 3 program and FDA approval stand.
US status: Psilocybin is Schedule I federally. No FDA approval of a psilocybin product appears in the sources reviewed; check the FDA for current status. Regulated state programs exist in Oregon and Colorado.
What small studies report about ayahuasca and depression, the serious antidepressant (MAOI) interaction risk, and how federal law treats ayahuasca.
US status: DMT is Schedule I federally. No FDA approval of ayahuasca for depression appears in the sources reviewed. Religious-use exemptions rest on RFRA, the 2006 O Centro ruling, and DEA agreements with specific churches.
4-HO-MET (metocin) is a directly active psilocin analogue, unlike prodrugs 4-AcO-DMT or psilocybin — Virginia and South Dakota schedule it by name; Florida bans it by chemical class.
US status: Not explicitly scheduled federally. Treated as Schedule I under the Federal Analogue Act (21 U.S.C. § 813) when intended for human consumption. Explicitly scheduled by name in Virginia and South Dakota; banned in Florida under its substituted-tryptamine class definition.
2C-B (4-bromo-2,5-dimethoxyphenethylamine) is a phenethylamine psychedelic explicitly listed on federal Schedule I since the mid-1990s — unlike 4-AcO-DMT or 4-HO-MET, no Federal Analogue Act theory is required to prosecute it.
US status: Schedule I. Listed by name at 21 CFR § 1308.11(d) (4-Bromo-2,5-dimethoxyphenethylamine, DEA Code 7392); became federally controlled in the mid-1990s. No FDA-registered clinical trials use 2C-B.
State-by-state guide to psilocybin and magic mushroom law in the US — federal status, Oregon, Colorado, and beyond.
US status: Schedule I federally. Legal licensed programs in Oregon (Measure 109) and Colorado (Prop 122). Decriminalized personal possession in Colorado. City deprioritization in 30+ jurisdictions. All other states: illegal.
Which psychedelics are legal in the US in 2026 — ketamine, psilocybin, ayahuasca, and the FDA pipeline.
US status: Ketamine: Schedule III, FDA-approved (Spravato), available nationwide. Psilocybin: Schedule I, legal in OR and CO. Ayahuasca/DMT: Schedule I, religious exemptions only. MDMA, LSD, ibogaine, 5-MeO-DMT: Schedule I, trials only.
Mescaline-containing cactus; federally protected for Native American Church use under AIRFA; slow-growing and in conservation crisis.
US status: Schedule I. Federal exemption under 42 U.S.C. §1996a and 21 CFR 1307.31 for Indians using peyote in bona fide traditional ceremonies. Colorado Prop 122 and Oregon Measure 109 explicitly exclude peyote.
No — kambo is a frog-peptide purge, not a psychedelic. Covers safety risks, the depression question, legal status, and what practitioners won’t tell you.
US status: Not a federally scheduled substance. Practitioners operate outside medical regulation; the FDA has not approved any kambo use. Practices vary by state.
Preparation and post-session work — the 2025 meta-analysis flags preparation hours as the strongest non-drug predictor of outcome.
US status: Not a scheduled substance; widely available through licensed therapists trained via Fluence, CIIS, Naropa, and other accredited programs.
Salvia divinorum is not federally scheduled in the US — but banned in roughly 29 states. It works through kappa opioid receptors, not serotonin, making it pharmacologically distinct from every other psychedelic.
US status: Not federally scheduled (DEA 'drug of concern' designation only). Criminally banned in approximately 29 states. Legal for adults in roughly 15 states. Age-restricted in California, Maine, and Maryland.
A–Z of the words used in psychedelic ceremony, integration, trauma work, and policy — defined in plain English.
US status: Reference page only — not a substance.
Why intention shapes outcome more than dose — plus a 14-prompt worksheet you can print and fill in before your session.
US status: Educational preparation guide — not a substance.
Which medications interact with psychedelics, how long the washout windows are, and the red-flag combinations that send people to the ER.
US status: Safety reference — not a substance and not medical advice.
A 14-day prep timeline covering medication washouts, intention work, body prep, and what to expect on arrival.
US status: Preparation guide — not a substance.
Fight, flight, freeze, and fawn — what each looks like, how triggers map to wounds, and why psychedelics surface them.
US status: Trauma education — not a substance.
The complete printable packing list for an ayahuasca, psilocybin, or 5-MeO-DMT retreat — plus what to leave at home.
US status: Packing reference — not a substance.
Pre-ceremony nutrition, hydration, supplements, sleep, and the foods to cut before a session.
US status: Nutrition and prep guide — not medical advice.
30+ books for psychedelic preparation, integration, trauma, and shadow work — annotated for what each one is for.
US status: Reading list — not a substance.
A printable 30-day journal with one prompt per day for the month after a psychedelic experience.
US status: Journal template — not a substance.
Ketamine is legal nationwide and FDA-approved as esketamine; psilocybin has strong trial data but legal access only in Oregon and Colorado.
US status: Ketamine is Schedule III and legal nationwide (Spravato is FDA-approved); psilocybin is Schedule I federally, with regulated access only in Oregon and Colorado.
How ketamine and SSRIs/SNRIs compare for depression — speed, evidence, cost, side effects, and which to pick when standard pills fail.
US status: Ketamine is Schedule III (legal, prescribed); SSRIs/SNRIs are standard prescription antidepressants.
Two leading options for hard-to-treat depression compared: how they work, FDA status, speed, cost, insurance, and side effects.
US status: Ketamine is a Schedule III controlled substance; esketamine (Spravato) is FDA-approved for treatment-resistant depression. TMS is an FDA-cleared medical device, not a scheduled drug.
Esketamine (Spravato) vs racemic ketamine for depression — FDA status, insurance coverage, cost, setting, and which to pick when.
US status: Spravato (esketamine) is Schedule III and FDA-approved for treatment-resistant depression (standalone use approved January 2025). Racemic ketamine is Schedule III and used off-label for depression, with no FDA approval for that use.
How LSD and psilocybin compare — duration, mechanism, legal access, and clinical trial data for depression and anxiety.
US status: Both LSD and psilocybin are Schedule I federally. Psilocybin has regulated legal access only in Oregon and Colorado; LSD has no regulated legal access anywhere in the US outside clinical trials.
How LSD and DMT compare — duration, legal status, religious-exemption access, and how far each drug program has reached in clinical trials.
US status: Both Schedule I federally. LSD has no state-level decriminalization anywhere in the US. DMT has Colorado's personal-possession decriminalization (Prop 122) plus four federally recognized religious exemptions for ayahuasca use.
How LSD and MDMA compare — mechanism, duration, legal access, and how far each FDA drug program has actually reached in 2026.
US status: Both Schedule I federally. Neither has state-level decriminalization or a religious exemption anywhere in the US — Colorado's Prop 122 explicitly excludes both LSD and MDMA from its decriminalized list.
How ibogaine and ketamine compare for addiction — legality, opioid and alcohol evidence, cardiac risk, session length, access, and cost.
US status: Ibogaine: Schedule I, no FDA approval, access only via international clinics or FDA-authorized (IND) trials. Ketamine: Schedule III nationwide, with esketamine (Spravato) FDA-approved for depression.
Two classic serotonergic psychedelics, compared on safety, legality, and the experience — including ayahuasca's serious MAOI drug interaction.
US status: Both Schedule I federally; ayahuasca is legal only via 4 US religious exemptions (most access is at retreats abroad), while psilocybin has regulated legal access in Oregon and Colorado.
Ketamine is legal nationwide and FDA-approved (as Spravato); ayahuasca is Schedule I with legal access limited to four US religious exemptions or retreats abroad.
US status: Ketamine is Schedule III and legal nationwide (Spravato is FDA-approved); ayahuasca is Schedule I federally, with legal access limited to four recognized US religious exemptions.
Ibogaine's strongest evidence is for opioid addiction and carries real cardiac risk; psilocybin's strongest evidence is for depression and anxiety, with regulated access in Oregon and Colorado.
US status: Both Schedule I federally with no FDA approval. Psilocybin has regulated access in Oregon and Colorado; ibogaine requires international travel (Mexico, Portugal, Costa Rica) or an FDA-authorized (IND) trial.
Ibogaine targets opioid addiction with a 24-72 hour session and real cardiac risk; ayahuasca targets depression and trauma in a 4-8 hour ceremony with a serious MAOI drug-interaction risk.
US status: Both Schedule I federally with no FDA approval. Ayahuasca has narrow legal access via four DEA-recognized US religious exemptions (most access is at retreats abroad); ibogaine has no US exemption and requires international travel or an FDA-authorized (IND) trial.
SNRIs, bupropion, and mirtazapine are equally evidence-based first-line options; ketamine (Spravato) is FDA-approved for treatment-resistant depression and psilocybin has positive Phase 3 data.
US status: SNRIs, bupropion, and mirtazapine are standard prescription antidepressants. Ketamine is Schedule III (Spravato FDA-approved). TMS is an FDA-cleared device. Psilocybin is Schedule I federally with regulated access only in Oregon and Colorado.
Both ketamine (Spravato) and TMS are available to veterans through VA health care, but they differ sharply in VA coverage consistency, speed, and PTSD evidence — a veteran-specific breakdown of which to ask for first.
US status: Both are legally available through VA health care. Spravato (esketamine) is Schedule III and FDA-approved for treatment-resistant depression; the VA covers it under the Mission Act at facilities that offer it. TMS is FDA-cleared (not a scheduled drug); many VA medical centers offer it, though availability and coverage details vary by facility.
Buspirone, SSRIs/SNRIs, and CBT are the standard first-line alternatives to benzodiazepines for anxiety; ketamine and psilocybin (MM120, Phase 3 for GAD) are the emerging psychedelic-adjacent options for anxiety that hasn't responded to those.
US status: Buspirone, SSRIs, and SNRIs are standard non-controlled or lower-schedule prescription medications. Ketamine is Schedule III (Spravato FDA-approved for depression, not anxiety). Psilocybin and LSD are Schedule I federally with no FDA approval for anxiety; MindMed's MM120 (LSD) is in Phase 3 trials for GAD.
Psychedelic therapy pairs a controlled psychedelic substance with professional support before, during, and after the session — with evidence strongest for ketamine (FDA-approved as Spravato) and psilocybin (positive Phase 3 trials in 2025).
US status: Ketamine (Schedule III) is legal nationwide; Spravato is FDA-approved. Psilocybin (Schedule I federally) has regulated access only in Oregon and Colorado. MDMA therapy is not FDA-approved.
Becoming a psychedelic therapist requires a clinical license (MD, NP, psychologist, LCSW, or similar) plus specialized training — unless you pursue the Oregon Measure 109 lay-facilitator route, which does not require a clinical license.
US status: Ketamine-assisted therapy is legal nationwide for licensed prescribers. Psilocybin facilitation is legal only in Oregon (Measure 109) and Colorado (Prop 122), each with their own training and approval requirements.
Most psychedelic companies are clinical-stage biotech — pre-revenue, funded by equity raises, and subject to large price swings around FDA decisions and trial readouts. Educational only; not investment advice.
US status: Psychedelic companies operate in a complex regulatory environment — their pipeline drugs range from Schedule III (ketamine) to Schedule I (psilocybin, MDMA). Scheduling status directly affects trial funding and approval timelines.
The federal test turns on chemistry and measured effect, not on which psychedelic inspired the molecule. Johnson & Johnson is leading an $85M round for Delix Therapeutics on the strength of that distinction.
US status: Zalsupindole and other neuroplastogens do not appear on any DEA controlled substance schedule today. They are developed under FDA investigational new drug (IND) exemptions, which also exclude them from Federal Analogue Act treatment during authorized research. No neuroplastogen has FDA marketing approval.
A curated list of the best psychedelic documentaries — with accuracy notes on where each film's claims align with or get ahead of the clinical evidence.
US status: The substances covered in these films range from FDA-approved (Spravato/ketamine) to Schedule I (psilocybin, MDMA, DMT, ibogaine). Legal access varies widely by drug and state.
Three ibogaine treatment centers reviewed for cardiac safety protocols, medical credentials, and integration support. Ibogaine is Schedule I in the US, so the programs run abroad, mostly in Mexico.
US status: Ibogaine is a Schedule I controlled substance in the US. The ibogaine programs on this list run outside the US, mostly in Mexico. Legal status in those jurisdictions varies.
Six vetted ayahuasca retreat centers reviewed for healer lineage, medical screening, integration quality, and safety infrastructure — primarily Peru and Costa Rica.
US status: Ayahuasca contains DMT, a Schedule I substance in the US. All retreat centers on this list operate outside US jurisdiction. Religious use under the Religious Freedom Restoration Act is a separate legal category.
Six at-home ketamine therapy providers compared by dose model, integration support, pricing, and published outcomes data.
US status: All providers listed are legal US telehealth services prescribing compounded ketamine under a valid US prescription. Spravato (esketamine) is separately FDA-approved for in-office administration only.
Eleven in-person ketamine and Spravato clinic operators compared by treatment format, location, and the price each publishes on its own site.
US status: Ketamine is a Schedule III controlled substance and is legal when prescribed by a licensed clinician; IV ketamine for depression is off-label. Spravato (esketamine) is FDA-approved and available only through a REMS program with in-office monitoring.
Eight psychedelic-assisted therapy practices in Oregon, Colorado, California, Texas and Nevada compared by format, location, and the price each publishes on its own site.
US status: Psilocybin services are lawful only through state-licensed providers in Oregon and Colorado; psilocybin is Schedule I federally. Ketamine is a Schedule III controlled substance, legal when prescribed by a licensed clinician.
Three psilocybin retreat centers reviewed across an Oregon-licensed service center, Jamaica, and the Netherlands — licensing, facilitator credentials, integration support, and cost.
US status: Oregon (Measure 109) and Colorado (Prop 122) have licensed psilocybin programs. Psilocybin is Schedule I in all other US states. Jamaica and the Netherlands operate under distinct legal frameworks.
On the pages we read, Rudick Law Group's homepage is the only one with dollar prices and McAllister Law Office's homepage is the only one offering a free consultation.
US status: Psilocybin is Schedule I federally and lawful only through state-licensed programs in Oregon and Colorado. Ketamine is a Schedule III controlled substance. Law firms advise on these rules; this page is not legal advice.
Ketamine therapy options for veterans — VETS grants, VA Spravato coverage, clinic-based infusions, and at-home programs with veteran discounts.
US status: Ketamine is a Schedule III controlled substance in the US. Spravato (esketamine) is FDA-approved for treatment-resistant depression and available at VA facilities. Compounded ketamine is prescribed off-label by licensed telehealth providers.
Where the evidence actually stands for psychedelic-assisted therapy in opioid, alcohol, and nicotine use disorders — with substance-specific deep dives.
US status: Ketamine is Schedule III and legally accessible; psilocybin and ibogaine remain Schedule I federally with no FDA-approved addiction indication. Oregon and Colorado run state psilocybin programs; ibogaine is available only via international clinics and a small number of FDA-IND trials.
What the evidence shows for ibogaine in opioid use disorder — the Texas $50M IMPACT trial, cardiac safety, and how patients taper methadone or suboxone before treatment.
US status: Ibogaine is Schedule I. No FDA-approved indication. Legal access is limited to FDA-IND trials (Texas IMPACT, DemeRx IB-001) and international clinics in Mexico, Costa Rica, and Portugal.
What the evidence shows for ibogaine in alcohol use disorder — smaller than the opioid signal, real cardiac risk, and what to know before booking a clinic.
US status: Ibogaine is Schedule I with no FDA-approved indication. Legal access for alcohol use disorder is limited to international clinics in Mexico, Costa Rica, and Portugal.
What the NYU 2022 JAMA Psychiatry proof-of-concept trial actually showed — 83% reduction in heavy drinking days — and where the research goes from here.
US status: Psilocybin is Schedule I federally with no FDA-approved indication. Oregon (Measure 109) and Colorado (Prop 122) have licensed adult-use programs; clinical-trial access remains the main path for AUD-specific care.
The Johns Hopkins pilot showed 80% biologically-verified smoking abstinence at six months — a stronger outcome than any FDA-approved cessation drug. Here is where the research stands.
US status: Psilocybin is Schedule I federally with no FDA-approved indication. Access for smoking cessation is currently limited to the Johns Hopkins NIDA-funded trial and adjacent research programs.
MDMA, ketamine, psilocybin, and ibogaine for PTSD compared — evidence tier, FDA status, and how legal access actually works in 2026.
US status: No psychedelic is FDA-approved for PTSD as of 2026. Ketamine is Schedule III and legally prescribed off-label; MDMA, psilocybin, and ibogaine remain Schedule I federally, with access limited to clinical trials, FDA Expanded Access, or (for psilocybin) Oregon/Colorado adult-use programs that are not PTSD-specific.
A single IV infusion typically runs $400–$800, a full 6-session induction $2,400–$6,000, at-home telehealth $129–$350/month, and Spravato $590–$885 per session before coverage. Insurance covers Spravato but rarely off-label ketamine — HSA/FSA generally do.
US status: Off-label ketamine therapy is legal nationwide for licensed prescribers. Spravato (esketamine) is FDA-approved for treatment-resistant depression and MDD with acute suicidal ideation, delivered through a REMS network.
Insurance rarely covers off-label ketamine infusion but does cover FDA-approved Spravato — with prior authorization. HSA and FSA funds are generally eligible for medically supervised sessions.
US status: Coverage is a payer question, not a legality question. Off-label ketamine is legal for licensed prescribers regardless of insurance.
Spravato's list price is around $590–$885 per treatment session before insurance. With commercial coverage and Janssen's withMe copay-support program, eligible patients often pay $10 or less per session; Medicare Part B typically covers Spravato after prior authorization.
US status: Spravato is FDA-approved for treatment-resistant depression and for MDD with acute suicidal ideation. It is administered in-clinic only, through the REMS certified-provider network.
At-home telehealth ketamine programs typically run $129–$350 per month for oral or sublingual troches, including provider visits, integration, and dosing. Prices vary widely by session cadence, membership tier, and whether integration therapy is bundled.
US status: At-home oral and sublingual ketamine is legal when prescribed by a licensed clinician. Spravato is never a take-home medication.
On Mindbloom's 6-session program, cancellation fees rise from $150 to the full $1,290 as prescriptions ship.
US status: Ketamine is Schedule III. Compounded ketamine prescribed for at-home use is not FDA-approved for any psychiatric condition; Spravato (esketamine) is FDA-approved and given only in certified settings.
Colorado's DORA held its Rule 5.4 facilitator continuing education hearing on October 8, 2026, and the Natural Medicine Division lists six 2026 rule items.
US status: Psilocybin, psilocin, DMT, ibogaine and mescaline remain Schedule I federally. Colorado's licensed program is state law and is not federal approval.
Harm reduction is the honest safety layer around psychedelic use — medication interaction screening, drug checking, set and setting, sitters, and integration — for people who will use whether or not there is a legal option.
US status: Harm-reduction information is legal and encouraged. Content is educational only and does not endorse illegal use of controlled substances.
Serotonin syndrome runs from mild (agitation, sweating, tremor) to life-threatening (high fever, seizures, muscle rigidity). Psychedelics that hit 5-HT2A/5-HT1A raise the risk when combined with SSRIs, MAOIs, tramadol, or methylene blue.
US status: Emergency medical information — not a substance and not medical advice. Suspected serotonin syndrome is a 911 call.
In the moment: quiet space, familiar sitter, controlled breathing, no benzodiazepines without a prescriber. The next morning through the next month: sleep, sunlight, therapist, no immediate re-dose. Most difficult experiences integrate — a few need professional care.
US status: Stabilization guidance — educational only, not medical advice. Suicidal ideation, prolonged psychosis, or serotonin-syndrome signs after psychedelic use are 911 or crisis-line calls.
Reagent kits (Marquis, Mecke, Simon's) reveal common adulterants and confirm whether a sample contains MDMA — they do not report purity or dose. Fentanyl test strips are a separate, mandatory second test given ongoing contamination reports.
US status: Reagent test kits are legal to purchase in most US states; possession of an MDMA sample is not. Educational only — the safest option is not to use unregulated substances.
Psychedelic career paths cluster into four tracks: clinical (KAP therapist, psychiatrist), facilitator (Oregon Measure 109, Colorado Prop 122), research (protocol nurse, coordinator, PI), and industry (drug developers, retreat operators). Compensation, credentialing, and legal risk differ sharply across the four.
US status: Career track legality varies: KAP is nationwide, Measure 109 is Oregon-only, Prop 122 is Colorado, MDMA and psilocybin therapy roles outside those states remain in clinical-research settings only.
Most psychedelic research openings are clinical-trial support roles — study coordinator, protocol nurse, data manager, statistician — at MAPS PBC, COMPASS Pathways, Usona Institute, and academic centers like Johns Hopkins, NYU, and UCSF. Prior psychedelic experience is not required.
US status: Research roles operate under FDA-authorized IND studies, so handling Schedule I substances in a trial setting is legal for credentialed staff.
Nurse roles in the psychedelic space fall into two buckets — CRNAs and RNs monitoring ketamine infusions in outpatient clinics, and RNs supporting MDMA or psilocybin trial dosing days. Neither role requires a formal 'psychedelic nurse' credential yet, but KAP training add-ons are the norm.
US status: Nursing roles in ketamine clinics are legal nationwide under standard state scope-of-practice. Trial roles operate under FDA IND authority.
Ketamine-assisted therapy is the one legal psychedelic-therapy track available nationwide. Any licensed clinician (MD, NP, PA, psychologist, LCSW, LPC, MFT) can add KAP through a training program like Polaris Insight, Fluence, or the Ketamine Training Center — typically 40–120 hours, $3,000–$10,000.
US status: Ketamine-assisted therapy is legal in all 50 states under standard off-label prescribing rules. No lay-facilitator pathway exists — KAP requires a clinical license.
Oregon's Measure 109 facilitator license requires 120 hours of core training plus a 40-hour practicum at an OHA-approved program, a background check, and a $2,000 initial license fee. Approved programs run $8,000–$15,000; the whole pathway takes 6–18 months.
US status: Psilocybin facilitation is legal only in Oregon under Measure 109. The certification does not confer legal authority to practice in any other state.
MDMA-assisted therapy training is offered through CIIS's Certificate in Psychedelic-Assisted Therapies (applications for 2027-28 open January 15, 2027) and Fluence's MDMA modules. MAPS PBC's program is not accepting applications, and Polaris Insight trains ketamine-assisted therapy only. A clinical license is required — no lay pathway exists. Cohorts are 100–200 hours, $3,000–$15,000.
US status: MDMA is Schedule I with no FDA approval yet. Trained therapists work in clinical-research and sponsor-affiliated settings; off-trial practice remains illegal.
Country-by-country legality of psilocybin, ayahuasca, and MDMA — Netherlands truffles, Portugal and Czech decriminalization, Jamaica and Costa Rica, Brazil and Peru, and Australia's prescribing program.
US status: Not a US-law page — see /guides/what-psychedelics-are-legal-in-the-us for the US-specific breakdown.
What 'legal highs' actually are — unscheduled novel psychoactive substances sold in UK/EU head shops — and why they are not the same as the Schedule I classic psychedelics this site covers.
US status: Not a controlled-substance category — 'legal highs' describes unscheduled novel psychoactive substances, mostly a UK/EU retail term.
What counts as a 'legal drug' — alcohol, caffeine, nicotine, and OTC/Rx medication — and where to find our psychedelic-specific legal-status guides.
US status: Not psychedelic-specific — see /guides/what-psychedelics-are-legal-in-the-us for that coverage.
Amanita muscaria gummies, hemp-derived cannabinoids, and kava — what is actually legal to buy, how it differs from psilocybin, and the real safety risks.
US status: Varies by product and state; none of these products contain psilocybin or another Schedule I psychedelic.
Common short-term effects — dissociation, nausea, blood-pressure changes — plus the long-term bladder risk from frequent, high-dose use.
US status: Schedule III. Spravato (esketamine) FDA-approved for TRD; ketamine off-label via clinics and telehealth.
A step-by-step walkthrough of a clinical KAP session — screening call, who's in the room, the dosing window, and integration after.
US status: Schedule III. Spravato (esketamine) FDA-approved for TRD; ketamine off-label via clinics and telehealth.
Ketamine vs electroconvulsive therapy for treatment-resistant depression — evidence strength, cognitive side effects, speed, and cost compared.
US status: Ketamine is a Schedule III controlled substance; esketamine (Spravato) is FDA-approved for treatment-resistant depression. ECT is a regulated medical procedure delivered via FDA-regulated devices, not a scheduled drug.
Medication switching, Spravato/ketamine, ECT, psychotherapy, and trial-stage psilocybin data compared as alternatives to transcranial magnetic stimulation for depression.
US status: Antidepressants and Spravato (esketamine) are FDA-approved prescription medications; ketamine is Schedule III off-label. ECT is an FDA-regulated medical procedure, not a scheduled drug. Psilocybin is Schedule I federally with no FDA approval for depression; access is limited to clinical trials or Oregon/Colorado licensed programs.
The small, brown, wood-loving mushroom that kills psilocybin foragers — species profile, spore print, and why it is misidentified.
US status: Not a controlled substance — Galerina marginata is a wild fungus, not a scheduled drug. Its danger is toxicological, not legal: ingestion is a medical emergency.
Also called 'funeral bell.' Contains the same amatoxins as the death cap. Here is the symptom timeline and what to do next.
US status: Not a scheduled drug. Suspected ingestion is a poison-control emergency — call 1-800-222-1222 (US) before symptoms start; do not wait.
Side-by-side identification: spore print, gill attachment, blueing reaction, veil ring, substrate, cluster pattern.
US status: Psilocybin is Schedule I federally; Galerina is not scheduled. The comparison here is a poisoning-prevention aid, not a foraging endorsement — see /guides/are-mushrooms-legal for the legal supply pathways in Oregon and Colorado.
The Pacific Northwest wood-mulch pairing foragers confuse most often — and the four features that actually separate them.
US status: Psilocybe cyanescens is Schedule I federally. Oregon operates licensed adult-use service centers (Measure 109) that do not require you to forage. Galerina marginata is not scheduled but is medically deadly.
Why field-guide ID of wild psilocybin mushrooms is the leading cause of amatoxin poisoning — and what the safer alternatives are.
US status: Psilocybin is Schedule I federally. Legal adult-use programs operate in Oregon (Measure 109) and Colorado (Prop 122). Wild foraging is illegal in most states AND unsafe regardless of legality.
The other deadly amatoxin psilocybin look-alike — a small lawn-and-mulch mushroom that carries the same toxin as the death cap. Species ID, spore print, and poisoning timeline.
US status: Not a controlled substance — Conocybe filaris is a wild fungus, not a scheduled drug. Its danger is toxicological, not legal: ingestion is a medical emergency (US Poison Help 1-800-222-1222).
Yopo's main active compound, bufotenine, is Schedule I federally, and no separate federal rule on the Anadenanthera tree or its seeds is on our record.
US status: Bufotenine, DMT and 5-MeO-DMT are Schedule I under 21 CFR 1308.11(d). The schedule entries name the chemicals and do not mention the Anadenanthera tree or its seeds.
Muscimol is absent from the federal drug schedules, yet the FDA calls Amanita muscaria and muscimol unapproved food additives and Louisiana lists Amanita muscaria.
US status: Muscimol is not named in 21 CFR 1308.11 to 1308.15 (Schedules I to V). The FDA has determined Amanita muscaria and muscimol are unapproved food additives, and Louisiana lists Amanita muscaria as a hallucinogenic plant.
Set and setting means the mindset a person brings and the environment around the experience. What two published papers say about context in psychedelic research.
US status: Psilocybin, psilocyn and MDMA are Schedule I federally (21 CFR 1308.11). Oregon (Measure 109) and Colorado (Prop 122) allow adult psilocybin access at state-regulated service centers.
What published sources report about combining MDMA with an SSRI: blunted effects in a citalopram study, serotonin syndrome reports, and why a prescriber decides.
US status: MDMA is Schedule I federally (21 CFR 1308.11, code 7405); MDMA-assisted therapy is available only in authorized research.
What published sources report about psilocybin and SSRI antidepressants: a controlled escitalopram study, a 2023 survey of weaker effects, trial stop rules, and why a prescriber decides.
US status: Psilocybin is Schedule I federally (21 CFR 1308.11, code 7437) and is investigational, not FDA-approved. Oregon and Colorado run state-regulated adult access programs, which are not FDA approval.
No consensus definition of treatment-resistant depression exists. Esketamine nasal spray won FDA approval in 2019, and psilocybin is not approved.
US status: Esketamine nasal spray (Spravato) is FDA-approved and prescribed in REMS-certified settings. Psilocybin is Schedule I federally (21 CFR 1308.11) and not approved for depression; Oregon and Colorado service centers are not depression treatment programs.
How to identify Psilocybe cubensis — cap, gills, purple-black spore print, and blue bruising — plus the look-alikes that send foragers to the hospital.
US status: Psilocybe cubensis is Schedule I federally (it contains psilocybin). Legal adult use exists only through Oregon (Measure 109) and Colorado (Prop 122) service centers. Wild picking is illegal in most states and unsafe regardless of legality.
Biphasic amatoxin poisoning — 6–24h latent, GI phase, deceptive false recovery, hepatorenal failure day 3–5. What ER teams do, and when to call poison control.
US status: Not applicable — amanitin is a naturally occurring toxin, not a drug. Suspected ingestion is a medical emergency. In the US, call 1-800-222-1222 (Poison Help) 24/7.
Combining two serotonergic psychedelics in the same session or on consecutive days raises the same interaction risks this site's medication-safety guide covers — and no clinical trial has studied the combination.
US status: Both Schedule I federally. Neither substance is legal for unsupervised recreational use in any US state; access is via FDA clinical trials (MDMA), Oregon Measure 109 or Colorado's Prop 122 Natural Medicine program (psilocybin only), or research settings.
The ayahuasca vine contains harmala alkaloids, not DMT — which is why it is not a federally scheduled substance in the US, and why that changes the moment it is brewed with a DMT-containing plant.
US status: Not federally scheduled — harmala alkaloids are absent from the CSA schedules, so the vine itself is not a controlled substance. Louisiana's La. R.S. 40:989.1 prohibits preparing Banisteriopsis for human consumption (ornamental use exempted). Any preparation containing DMT is Schedule I regardless of the vine.
The Amazonian dieta is not the no-salt-no-sugar diet a retreat asks you to follow — it is weeks of isolation with a single plant. Here is what it involves, what is legal, and where people have been hurt.
US status: Mixed and plant-specific. Most dieta plants (bobinsana, chuchuhuasi, ajo sacha) are not scheduled anywhere in the US. Ayahuasca ceremonies held alongside a dieta involve DMT, which is Schedule I. Dietas are practiced abroad, most commonly in Peru, where traditional plant medicine is legally protected.
Calliandra angustifolia — an Amazonian dieta plant with a heart-opening reputation, no established psychedelic action, and no controlled-substance status in the US.
US status: Not a controlled substance — Calliandra angustifolia does not appear on the federal CSA schedules or any state schedule. Legality is not a safety clearance: no dose is established and the interaction picture with serotonergic medication is unstudied.
Hapé (rapé) is an Amazonian snuff made from high-nicotine Nicotiana rustica tobacco: not a hallucinogen, not a controlled substance, and regulated in the US as smokeless tobacco.
US status: Not a controlled substance. Regulated by the FDA as smokeless tobacco (dry snuff); federal minimum age of sale is 21 (Tobacco 21). Online sales and shipping fall under the PACT Act.
Adults 21 and older can buy rapé in the US, but online sellers must follow PACT Act delivery rules, the USPS cannot carry it, and some states restrict flavored blends.
US status: Legal to buy at 21+ as smokeless tobacco. Online sellers must register, pay excise taxes, and deliver by adult-signature carrier (PACT Act); USPS cannot carry commercial orders (18 U.S.C. 1716E).
Comparing a supervised ibogaine reset against self-managed kratom for opioid withdrawal, including the DEA's July 2026 action on concentrated 7-OH.
US status: Ibogaine: Schedule I, no FDA approval, access only via international clinics or FDA-authorized (IND) trials. Kratom leaf: federally unscheduled but banned in 7 states; concentrated 7-hydroxymitragynine (7-OH) products above a set threshold moved toward Schedule I under the DEA's July 2026 temporary scheduling order.
Ketamine and Spravato are noninferior to ECT in a 2023 head-to-head trial with fewer memory side effects; TMS avoids memory risk entirely; MAOIs and psilocybin trials are further options for treatment-resistant depression.
US status: Spravato (esketamine) is Schedule III and FDA-approved. IV/IM ketamine is off-label. TMS is an FDA-cleared device. MAOIs are standard prescription antidepressants. Psilocybin is Schedule I federally with regulated access only in Oregon and Colorado. ECT is not a scheduled substance and is a regulated medical procedure.
DMT resolves in 15 to 20 minutes with no licensed US access; psilocybin runs 4 to 6 hours with live Oregon and Colorado service-center programs and deeper depression-trial evidence.
US status: Both DMT and psilocybin are Schedule I federally with no FDA approval. Colorado decriminalized personal DMT possession under Proposition 122; Oregon (Measure 109) and Colorado both run licensed psilocybin service-center programs that do not cover DMT.
Antidepressants are FDA-approved and prescribable nationwide for $10 to $75 a month; psilocybin has real Phase 3 trial data but no FDA approval, and SSRIs can blunt its effects.
US status: Psilocybin is Schedule I federally with no FDA approval, though it holds two active FDA Breakthrough Therapy designations; regulated non-medical access exists only in Oregon (Measure 109) and Colorado (Proposition 122). SSRIs and SNRIs are unscheduled, FDA-approved prescription medications available nationwide.
Molly is a nickname for MDMA, not a purer or separate drug; the name says nothing about what a product contains, and both are Schedule I.
US status: MDMA, however it is named (Molly, ecstasy, or otherwise), is Schedule I federally with no FDA approval; US access is limited to clinical trials and FDA Expanded Access.
Psilocybin is studied mainly for depression and MDMA for PTSD; neither is FDA-approved, and only psilocybin has licensed US state programs (Oregon and Colorado).
US status: Both are Schedule I federally with no FDA approval. Regulated non-medical psilocybin access exists in Oregon (Measure 109) and Colorado (Proposition 122); no US state runs a licensed MDMA program.
Spravato, TMS, ECT, antidepressant changes, and psilocybin compared on FDA status, cost, and speed for people weighing options beyond ketamine therapy.
US status: Ketamine is Schedule III and used off-label for depression; Spravato, TMS, ECT, and antidepressants are approved or cleared options; psilocybin is Schedule I with no FDA approval and narrow state-licensed access.
Suboxone is FDA-approved with decades of trial data and a built-in overdose ceiling; kratom is an unregulated supplement with real access appeal but no standardized dose and rising poisoning reports.
US status: Suboxone is FDA-approved (2002) and a Schedule III prescription medication. Kratom leaf is federally unscheduled (a 2016 DEA scheduling notice was withdrawn) but banned in several states; concentrated 7-hydroxymitragynine (7-OH) products moved toward Schedule I in July 2026.
Pregabalin shares gabapentin's mechanism, duloxetine and buspirone carry direct FDA anxiety approvals gabapentin lacks, and ketamine has early off-label evidence for treatment-refractory anxiety.
US status: Gabapentin is not federally controlled but is Schedule V in at least 8 states. Pregabalin is Schedule V federally. Duloxetine, buspirone, and hydroxyzine are not controlled substances. Ketamine is Schedule III and carries no FDA approval for any anxiety disorder.
Federally Schedule I at any dose, unapproved by the FDA, and unsupported by the best-controlled evidence — the 2021 Imperial College self-blinding study found placebo groups matched real-dose gains.
US status: Schedule I federally at any dose, including microdoses. Oregon (Measure 109) and Colorado (Prop 122) license only supervised, on-site, single-session psilocybin administration — neither covers take-home microdosing.
Definium's DT120 is an investigational LSD tablet: three positive sponsor-reported Phase 3 readouts, Breakthrough status, no FDA approval yet, and LSD remains Schedule I.
US status: Investigational, not FDA-approved. LSD is Schedule I federally; no state has a regulated therapeutic program or has decriminalized it. Access is through clinical trials only.
No psychedelic is FDA-approved for anxiety. What two small 2016 trials in patients with life-threatening cancer found, what they do not show, and where psilocybin stands under federal and state law.
US status: Schedule I federally (21 U.S.C. § 812); not FDA-approved for any anxiety disorder. Oregon (Measure 109) and Colorado (Prop 122) allow adult access at state-regulated service centers that are not anxiety-specific treatment programs.
A coach and a licensed therapist are different categories. How licensure, ethics oversight, insurance billing, and credentials differ for psychedelic integration.
US status: Talking with an integration therapist about a psychedelic experience is legal everywhere in the US; the regulated part is the substance. Psilocybin has licensed regulated access only in Oregon and Colorado; MDMA and classic psychedelics remain Schedule I outside clinical trials.
Psilocybin is not FDA-approved for depression. What the Johns Hopkins and COMPASS trials found, where COMP360 stands, and how federal and state law treat it.
US status: Schedule I federally (21 U.S.C. § 812); not FDA-approved for any depressive disorder. Oregon (Measure 109) and Colorado (Prop 122) allow adult access at state-regulated service centers that are not depression treatment programs.
No psychedelic is FDA-approved for PTSD. What the VA is researching, what the 2026 executive order changes, and what DAV announced.
US status: Psilocybin, MDMA and ibogaine are Schedule I federally (21 U.S.C. § 812) and not FDA-approved for any indication; lawful access is through authorized research. Executive Order 14401 does not reschedule any psychedelic.
Advertising ketamine therapy is legal; what isn't is calling an off-label treatment “FDA-approved,” promising a cure, or skipping the risk disclosures the FTC and state medical boards require.
US status: Advertising ketamine treatment is legal nationwide. Ads become unlawful when they misstate FDA approval status, omit material risks, or make unsubstantiated guarantees — enforceable under FTC Act Section 5, state UDAP law, and state medical-board rules.
Each therapy guide is built from peer-reviewed primary sources — mostly PubMed-indexed trials, FDA advisory committee packets, and state/federal policy documents — not secondary summaries. We link the underlying papers inline so you can verify any claim.
Supplemental pieces from the legacy archive.
Psilocybin is illegal under US federal law (Schedule I, no FDA approval). Oregon and Colorado offer limited legal access for therapy. Learn about federal, state, and research status here.
879 words · Updated Oct 21, 2026
Psilocybin is legal for supervised use at licensed centers in Oregon (Measure 109), but remains federally illegal and is not allowed for personal possession outside these settings. Learn the details.
811 words · Updated Oct 21, 2026
MDMA is illegal for general use in the US under Schedule I of the Controlled Substances Act. No FDA-approved medical use exists; access is only via clinical trials. Learn about the legal context and research pathways.
771 words · Updated Oct 21, 2026
LSD is illegal in the US under federal law as a Schedule I controlled substance. Exceptions exist for approved research, such as MindMed's MM120 trials. Learn the facts and key regulatory details.
713 words · Updated Oct 21, 2026
Ibogaine is illegal for personal or clinical use in the US under federal law (Schedule I, no FDA approval). Research is permitted under strict controls, with some states funding studies. Learn more about the legal landscape.
763 words · Updated Oct 21, 2026
DMT is illegal in Iowa under both federal and state law, classified as a Schedule I controlled substance. No state-level reform or therapeutic program exists. See the legal status and context.
707 words · Updated Oct 21, 2026
Ketamine is legal in the US as a Schedule III controlled substance with a valid prescription. FDA-approved for anesthesia and, as esketamine, for treatment-resistant depression under strict protocols. Off-label use is widespread but not FDA-approved.
827 words · Updated Oct 19, 2026
Psilocybin is decriminalized for adults 21+ in Colorado under Prop 122. Licensed healing centers offer supervised use, but retail sales are illegal and federal Schedule I law still applies. Learn more about Colorado's psilocybin law.
888 words · Updated Oct 19, 2026
Psilocybin mushrooms are illegal in Michigan under federal and state law. Learn about current statutes, recent legislative efforts, and how Michigan compares to states like Oregon and Colorado.
847 words · Updated Oct 19, 2026
DMT is decriminalized for personal use by adults 21+ in Colorado, but remains illegal federally. Learn how state and federal laws interact, and what Colorado's Natural Medicine Health Act means for DMT.
871 words · Updated Oct 19, 2026
DMT is illegal in every U.S. state under federal law as a Schedule I substance, with only rare, specific exemptions. Learn about the legal status, state reforms, and research pathways.
790 words · Updated Oct 19, 2026
DMT is classified as a Schedule I controlled substance under US federal law, making it illegal to possess, manufacture, or distribute except in rare, regulated circumstances. Learn the details and exceptions.
746 words · Updated Oct 19, 2026
Are psychedelics legal in the US? This explainer details federal Schedule I status, FDA approval, and state-level programs in Oregon and Colorado, with a state-by-state overview.
865 words · Updated Sep 28, 2026
Recent time-sensitive briefings that touch on these therapies, their evidence base, or their legal status.
A new phase 2 trial finds psilocybin reduces inflammation in Parkinson’s disease, suggesting a possible disease-modifying role. This insight could shift research and regulatory focus toward psychedelics’ neuroprotective potential, but key risks and unknowns remain.
Oct 21, 2026
A new secondary analysis of a U.S. MDMA-assisted therapy trial for social anxiety disorder reveals that session experiences of interconnectedness and self-transcendence predict post-treatment wellbeing, but not symptom reduction. This finding could reshape outcome measures in future psychedelic research and regulatory review.
Oct 20, 2026
A robust deep learning model now enables more accurate, scalable sleep stage classification in preclinical studies, even under varied pharmacological interventions—advancing psychedelic and CNS drug research reliability.
Oct 20, 2026
Optimi Health has finalized GMP-grade MDMA manufacturing for a Phase 3 PTSD trial, addressing key supply and regulatory hurdles. This development signals maturing industry capacity and highlights both opportunities and unresolved risks in psychedelic-assisted therapy research.
Oct 20, 2026
Optimi Health has finalized MDMA production for Phase 3 PTSD trials in Canada and Israel, and for commercial supply in Australia, advancing international clinical research and highlighting progress in psychedelic medicine supply chains.
Oct 20, 2026
This briefing examines how Michael Pollan’s works have shaped Western narratives on psilocybin, raising unresolved ethical, cultural, and policy issues regarding Mazatec Indigenous rights and benefit-sharing as the psychedelic industry expands.
Oct 19, 2026
Get the daily briefing in your inbox
Law, clinical science, and policy signal on psychedelic research — on our publish cadence. Start at the The Psychedelic Journal homepage.
Subscribe freeSuggest a tool, topic, or improvement that would make this site more useful.